Document is current
Any future updates will be listed below
-
Authors
He, Chuyu https://orcid.org/0000-0001-6232-4594
Wang, Xuejuan
Chiou, Yi-Shiou
Basappa, Basappa https://orcid.org/0000-0002-8844-468X
Zhu, Tao https://orcid.org/0000-0003-4130-1144
Pandey, Vijay https://orcid.org/0000-0001-8704-0694
Lobie, Peter E. https://orcid.org/0000-0002-8445-184X
- License Information
-
More Information
Article History
Received: 27 August 2024
Revised: 13 January 2025
Accepted: 22 January 2025
First Online: 7 February 2025
Competing interests
: The authors declare the following competing interests: PEL has previously consulted for Perseis Therapeutics Ltd. PEL are named on PCT application numbers WO 2006/69253 and WO 2008/042435 and US provisional application number 61/059558 and derivatives thereof. VP, BB, and PEL are named as inventors on PCT application WO/2018/226155 (PCT/SG2018/050277), Compounds, As Inhibitors of TFF3 Dimerization, Methods and Applications Thereof (and derivatives thereof including US Patent 11,141,402). PEL is an equity holder in Sinotar Pharmaceuticals Ltd which currently holds PCT/SG2018/050277 and derivatives thereof including issued US Patent no. 11,141,402. All other authors have no competing interests to declare.
: All animal care and experimental protocols for in vivo studies were approved by the Laboratory Animal Ethics Committee (Certificate number: YW) at Peking University Shenzhen, and ethical approval was obtained from Tsinghua Shenzhen International Graduate School (Number: 9, Year 2020). No human research participants were involved in the present study.
